A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes

Diabetes

Volumn 51, Issue 5, 2002, Pages 1453-1460

  Tsutsumi, Manami ^a   Claus, Thomas H ^a   Liang, Yin ^a   Li, Yaxin ^a   Yang, Ling ^a   Zhu, Jian ^a   Cruz, Fernando Dela ^a   Peng, Xianbu ^a   Chen, Hongxing ^a   Yung, Stephanie L ^a   Hamren, Sarah ^a   Livingston, James N ^a   Pan, Clark Q ^a,b  

^a BAYER CORPORATION   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 55 9837; GLUCOSE; HORMONE RECEPTOR STIMULATING AGENT; INSULIN; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SYNTHESIS; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL; PRIORITY JOURNAL; RAT; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; WATER RETENTION;

EID: 0036312399     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.5.1453     Document Type: Article

References (49)

1. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells
2. Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38)
3. Polypeptide with broad biological activity: Isolation from small intestine
4. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide
5. Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intra-pancreatic regulator of insulin secretion from islet beta-cells
6. Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat
7. A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide
8. PACAP and PACAP receptors in insulin producing tissues: Localization and effects
9. Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells
10. Glycogenolytic activity of pituitary adenylate cyclase activating polypeptide (PACAP) in vivo and in vitro
11. PACAP stimulates glucose output from the perfused rat liver
12. Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner
13. PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice
14. Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans
15. Development of high affinity selective VIP 1 receptor agonists
16. In vitro properties of a high affinity selective antagonist of the VIP 1 receptor
17. C-terminally shortened pituitary adenylate cyclase-activating peptides (PACAP) discriminate PACAP I, PACAP II-VIP1 and PACAP II-VIP 2 recombinant receptors
18. Concordant glucose induction of glucokinase, glucose usage and glucose stimulated insulin release in pancreatic islets maintained in organ culture
19. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice
20. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets
21. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions
22. The use of insulin secretagogues in the treatment of type 2 diabetes
23. Experimental evidence for vasoactive intestinal peptide as the cause of the watery diarrhea syndrome
24. Vasoactive intestinal polypeptide (VIP) as a mediator of the watery diarrhea syndrome
25. VIPoma syndrome
26. Regional haemodynamic responses to pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide in conscious rats
27. Analysis of cardiovascular responses to PACAP-27, PACAP-38, and vasoactive intestinal polypeptide
28. Insulinotropic glucagon-like peptides
29. Role of cAMP in upregulation of insulin secretion during the adaptation of islets of Langerhans to pregnancy
30. 2+: New insights into stimulus-secretion coupling
31. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line
32. Insulinotropic hormone glucagon-like peptide-1(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells
33. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells
34. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element
35. Molecular and functional characterization of pituitary adenylate cyclase-activating polypeptide (PACAP-38)/vasoactive intestinal polypeptide receptors in pancreatic β-cells and effects of PACAP-38 on components of the insulin secretory system
36. Control of insulin gene expression in pancreatic β-cells and in an insulin-producing cell line, RIN-5F cells. I. Effects of glucose and cyclic AMP on the transcription of insulin mRNA
37. The β cell transcription factors and development of the pancreas
38. The glucagon-like peptides
39. Measuring the balance between insulin synthesis and insulin release
40. Glucagon stimulates expression of the inducible CAMP early repressor and suppresses insulin gene expression in pancreatic β-cells
41. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
42. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
43. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance
44. Pharmacokinetic profile of the long-acting GLP-1 derivative NN2211 in healthy male subjects
45. Insulinotropic actions of exendin4 and glucagon-like peptide-1 in vivo and in vitro
46. PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance
47. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type 1 receptor agonist
48. PACAP stimulates catecholamine release from adrenal medulla: A novel noncholinergic secretagogue
49. Hemodynamic actions of systemically injected pituitary adenylate cyclase activating polypeptide-27 in the rat